HC
HanKang Capital is a venture capital firm that primarily focuses on investments within the healthcare sector, including biomedicine, medical equipment, diagnostic reagents, and medical services. Their strategy involves in-depth research into major diseases and unmet medical needs, investing in early-stage companies with strong teams and technology platforms to empower biomedical innovation.
67% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-b (67% of deals). Average disclosed round size is $63.0M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$700M
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
| AAusperBio | Series B | $63M | Sep 2025 |
| AAusperBio | Series A | $37M | Jul 2024 |
Top Co-Investors
Yuanbio Venture Capital2 shared
Genesis Investments2 shared
CDH Investments1 shared
LAV1 shared
Foresite Capital1 shared
Quan Funds1 shared
RA Capital Management1 shared
Logos Capital1 shared
OrbiMed1 shared
Last updated: 10 April 2026